Complexation of 2-hydroxynicotinic and 3-hydroxypicolinic acids with zinc(II). Solution state study and crystal structure of trans-diaqua-bis-(3-hydroxypicolinato)zinc(II)

[1]  A. Tapparo,et al.  Evaluation of 3,4‐Hydroxypyridinecarboxylic Acids as Possible Bidentate Chelating Agents for Aluminium(III): Synthesis and Metal−Ligand Solution Chemistry , 2002 .

[2]  R. Yokel.  Aluminum chelation principles and recent advances , 2002 .

[3]  R. Hider,et al.  Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. , 2002, Journal of medicinal chemistry.

[4]  R. Hider,et al.  Design of clinically useful iron(III)‐selective chelators , 2002, Medicinal research reviews.

[5]  T. Kruck,et al.  Synthesis of feralex a novel aluminum/iron chelating compound. , 2002, Journal of inorganic biochemistry.

[6]  A. Tapparo,et al.  New possible chelating agents of clinical interest for iron(III): 2-hydroxynicotinic acid and 3-hydroxypicolinic acid. A thermodynamic study. , 2001, Annali di chimica.

[7]  Yu Zhang,et al.  Critical evaluation of thermodynamics of complex formation of metal ions in aqueous solutions , 2001 .

[8]  J. Domingo,et al.  Evaluation of the protective activity of deferiprone, an aluminum chelator, on aluminum-induced developmental toxicity in mice. , 2000, Teratology.

[9]  A. Kolnagou,et al.  Deferiprone for thalassaemia , 2000, The Lancet.

[10]  B. Faller,et al.  Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network. , 2000, Journal of medicinal chemistry.

[11]  R. Hider,et al.  Design, Synthesis and Evaluation of N‐Basic Substituted 3‐Hydroxypyridin‐4‐ones: Orally Active Iron Chelators with Lysosomotrophic Potential , 2000, The Journal of pharmacy and pharmacology.

[12]  G. Micera,et al.  Solution speciation and spectral studies on oxovanadium(IV) complexes of pyridinecarboxylic acids , 2000 .

[13]  M. Drew,et al.  Coordination modes of 3-hydroxypicolinic acid: synthesis and crystal structures of palladium(II), platinum(II) and rhenium(V) complexes , 2000 .

[14]  B. Bernard,et al.  First human studies with a high-molecular-weight iron chelator. , 2000, The Journal of laboratory and clinical medicine.

[15]  G. Faa,et al.  Iron chelating agents in clinical practice , 1999 .

[16]  A. Tapparo,et al.  Complex formation between aluminium(III) and two hydroxy-aromatic ligands : 2-hydroxyphenylethanone and 2-hydroxybenzeneacetic acid , 1999 .

[17]  R. Bertani,et al.  Complex formation between aluminium(III) and two pyridine derivatives : 2-hydroxynicotinic and 3-hydroxypicolinic acid , 1999 .

[18]  A. Bodor,et al.  Siderophore analogues: a new macrocyclic tetraamine tris(hydroxamate) ligand; synthesis and solution chemistry of the iron(III), aluminium(III) and copper(II) complexes† , 1999 .

[19]  F. Albert Cotton,et al.  Advanced Inorganic Chemistry , 1999 .

[20]  K. Fleming,et al.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.

[21]  C. Orvig,et al.  Complexation of gallium(III) by 2-hydroxynicotinic acid and 3-hydroxypicolinic acid in aqueous solution , 1998 .

[22]  D. Richardson,et al.  Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. , 1998, The Journal of laboratory and clinical medicine.

[23]  J. D. Preez,et al.  The coordination mode of 3-hydroxypicolinic acid in oxorhenium (V) complexes. Crystal and molecular , 1998 .

[24]  A. Bianchi,et al.  Synthesis and characterisation of two new catechol-based iron(III) ion-sequestering agents , 1998 .

[25]  J. Domingo,et al.  Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. , 1996, Journal of toxicology and environmental health.

[26]  T. Kiss,et al.  The bioinorganic chemistry of aluminum , 1996 .

[27]  G. Kontoghiorghes.  Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. , 1995, Toxicology letters.

[28]  G. Kontoghiorghes.  New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. , 1995, The Analyst.

[29]  G. Brittenham,et al.  The Development of Iron Chelators for Clinical Use , 1993 .

[30]  Owen Johnson,et al.  The development of versions 3 and 4 of the Cambridge Structural Database System , 1991, J. Chem. Inf. Comput. Sci..

[31]  L.‐O. Oehman.  Equilibrium and structural studies of silicon(IV) and aluminum(III) in aqueous solution. 17. Stable and metastable complexes in the system hydrogen (+)-aluminum(3+)-citric acid , 1988 .

[32]  O. Jøns,et al.  Formation of aluminium and zinc complexes with picolinic acid. A potentiometric investigation , 1988 .

[33]  R. Gleckman,et al.  Drug therapy reviews: nalidixic acid. , 1979, American journal of hospital pharmacy.

[34]  E. Underwood.  Trace Elements in Human and Animal Nutrition , 1956, Agronomy Journal.

[35]  M. Paabo,et al.  Use of the glass electrode in deuterium oxide and the relation between the standardized pD (paD) scale and the operational pH in heavy water , 1968 .